TY - JOUR
T1 - Severity of Acute COVID-19 in Children <18 Years Old March 2020 to December 2021
AU - Forrest, Christopher B.
AU - Burrows, Evanette K.
AU - Mejias, Asuncion
AU - Razzaghi, Hanieh
AU - Christakis, Dimitri
AU - Jhaveri, Ravi
AU - Lee, Grace M.
AU - Pajor, Nathan M.
AU - Rao, Suchitra
AU - Thacker, Deepika
AU - Bailey, L. Charles
N1 - Publisher Copyright:
© 2022 by the American Academy of Pediatrics.
PY - 2022/4
Y1 - 2022/4
N2 - BACKGROUND AND OBJECTIVES: High transmissibility of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant led to increased coronavirus disease 2019 (COVID-19) cases, but its effect on severe illness among children is less clear. This study evaluated changes in COVID-19 severity from March 1, 2020, to December 30, 2021. METHODS: We examined electronic health record data from encounters that occurred in outpatient and inpatient settings in 9 health systems participating in PEDSnet. The study sample included children aged <18 years with a positive viral test for SARS-CoV-2. Severity was categorized as asymptomatic, mild (symptoms), moderate (moderately severe COVID- 19-related conditions such as gastroenteritis, dehydration, and pneumonia), or severe (unstable COVID-19-related conditions, ICU admission, or mechanical ventilation). RESULTS: The number of patients classified as asymptomatic was 54 948 (66.4%), with 22 303 (26.9%) being mild, 3781 (4.6%) being moderate, and 1766 (2.1%) being severe. In 2021, patients with moderate to severe illness peaked in June (13.5%), declining to December (8.1%). Compared with July 2020 to February 2021, the adjusted odds ratio for moderate to severe illness was highest in June 2021 (adjusted odds ratio, 2.8; 95% confidence interval, 2.2-3.6) and lower in July to December 2021, when the Delta variant predominated. The adjusted odds ratio for moderate to severe illness among children with complex chronic conditions was 4.2 (95% confidence interval, 3.9-4.5). CONCLUSIONS: Although 1 in 16 children infected with the SARS-CoV-2 virus experienced moderate or severe illness, the risk of severe disease did not change with the emergence of the Delta variant, despite its high transmissibility.
AB - BACKGROUND AND OBJECTIVES: High transmissibility of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant led to increased coronavirus disease 2019 (COVID-19) cases, but its effect on severe illness among children is less clear. This study evaluated changes in COVID-19 severity from March 1, 2020, to December 30, 2021. METHODS: We examined electronic health record data from encounters that occurred in outpatient and inpatient settings in 9 health systems participating in PEDSnet. The study sample included children aged <18 years with a positive viral test for SARS-CoV-2. Severity was categorized as asymptomatic, mild (symptoms), moderate (moderately severe COVID- 19-related conditions such as gastroenteritis, dehydration, and pneumonia), or severe (unstable COVID-19-related conditions, ICU admission, or mechanical ventilation). RESULTS: The number of patients classified as asymptomatic was 54 948 (66.4%), with 22 303 (26.9%) being mild, 3781 (4.6%) being moderate, and 1766 (2.1%) being severe. In 2021, patients with moderate to severe illness peaked in June (13.5%), declining to December (8.1%). Compared with July 2020 to February 2021, the adjusted odds ratio for moderate to severe illness was highest in June 2021 (adjusted odds ratio, 2.8; 95% confidence interval, 2.2-3.6) and lower in July to December 2021, when the Delta variant predominated. The adjusted odds ratio for moderate to severe illness among children with complex chronic conditions was 4.2 (95% confidence interval, 3.9-4.5). CONCLUSIONS: Although 1 in 16 children infected with the SARS-CoV-2 virus experienced moderate or severe illness, the risk of severe disease did not change with the emergence of the Delta variant, despite its high transmissibility.
UR - http://www.scopus.com/inward/record.url?scp=85128001434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128001434&partnerID=8YFLogxK
U2 - 10.1542/peds.2021-055765
DO - 10.1542/peds.2021-055765
M3 - Article
C2 - 35322270
AN - SCOPUS:85128001434
SN - 0031-4005
VL - 149
JO - Pediatrics
JF - Pediatrics
IS - 4
M1 - e2021055765
ER -